Sky Century Investment (SKYI) Cash from Financing Activities (2012 - 2026)
Sky Century Investment's (SKYI) quarterly Cash from Financing Activities came in at $86222.0 in Q2 2026, up 729.7% year-on-year from $10392.0 in Q2 2025, and up 12043.94% on a QoQ basis from $710.0 in Q1 2026.
Sky Century Investment (SKYI) Cash from Financing Activities (2012 - 2026) Analysis & Trends
Sky Century Investment (SKYI) has 6 years of Cash from Financing Activities data on file, last reported at $86222.0 in Q2 2026.
- On a quarterly basis, Cash from Financing Activities rose 729.7% year-over-year to $86222.0 in Q2 2026; TTM through May 2026 was $111132.0, a 89.5% increase from a year earlier, with the FY2025 full-year figure at $46136.0, up 59.08% from the prior year.
- Cash from Financing Activities for Q2 2026 stood at $86222.0, up from $710.0 in the prior quarter.
- Over the last five years, Cash from Financing Activities for SKYI reached as high as $86222.0 in Q2 2026 and fell as low as $710.0 in Q1 2026.
- Historically, Cash from Financing Activities has averaged $21958.9 across 3 years, with a median of $11668.5 in 2024.
- On a YoY basis, Cash from Financing Activities climbed as much as 729.7% in 2026 and fell as far as 97.15% in 2026.
- Year by year, Cash from Financing Activities stood at $10827.0 in 2024, then soared by 123.52% to $24200.0 in 2025, then surged by 256.29% to $86222.0 in 2026.
- Per Business Quant data, the three most recent Cash from Financing Activities figures were $86222.0 in Q2 2026, $710.0 in Q1 2026, and $24200.0 in Q4 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 13.00 Mn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | -840.00 Mn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | -494.13 Mn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | -1.48 Bn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | - |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -203.80 Mn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | -86.10 Mn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -65.00 Mn |
| 10 | Sky Century Investment | 1.06 Mn | 1.06 Mn | 26,045.00 | 86,222.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| May 31, 2026 | 86,222.00 |
| May 31, 2026 | 86,222.00 |
| Feb 28, 2026 | 710.00 |
| Feb 28, 2026 | 710.00 |
| Nov 30, 2025 | 24,200.00 |
| Nov 30, 2025 | 24,200.00 |
| May 31, 2025 | 10,392.00 |
| May 31, 2025 | 10,392.00 |
| Feb 28, 2025 | 24,917.00 |
| Feb 28, 2025 | 24,917.00 |
| Nov 30, 2024 | 10,827.00 |
| Nov 30, 2024 | 10,827.00 |
| Aug 31, 2024 | 12,510.00 |
| Aug 31, 2024 | 12,510.00 |
| May 31, 2024 | 5,893.00 |
| May 31, 2024 | 5,893.00 |
| May 31, 2014 | 1,130.00 |
| May 31, 2014 | 1,130.00 |
| Nov 30, 2013 | 10,350.00 |
| Nov 30, 2013 | 10,350.00 |